| Literature DB >> 24669281 |
Paulo C Schenkel1, Rafael O Fernandes1, Vinícius U Viegas1, Cristina Campos1, Tânia R G Fernandes1, Alex Sander da Rosa Araujo1, Adriane Belló-Klein1.
Abstract
We tested the influence of estrogen on coronary resistance regulation by modulating nitric oxide (NO) and hydrogen peroxide (H2O2) levels in female rats. For this, estrogen levels were manipulated and the hearts were immediately excised and perfused at a constant flow using a Langendorff's apparatus. Higher estrogen levels were associated with a lower coronary resistance, increased nitric oxide bioavailability, and higher levels of H2O2. When oxide nitric synthase blockade by L-NAME was performed, no significant changes were found in coronary resistance of ovariectomized rats. Additionally, we found an inverse association between NO levels and catalase activity. Taken together, our data suggest that, in the absence of estrogen influence and, therefore, reduced NO bioavailability, coronary resistance regulation seems to be more dependent on the H2O2 that is maintained at low levels by increased catalase activity.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24669281 PMCID: PMC3941593 DOI: 10.1155/2014/159852
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Coronary perfusion pressure (CPP) (in mmHg) of the different experimental groups before ischemia and after reperfusion. Values are expressed as mean ± S.D. of 4–6 animals/group. *Significantly different from TYRODE-SHAM (P < 0.05); #significantly different from L-NAME-SHAM (P < 0.05); †significantly different from TYRODE-OVX + E2 (P < 0.05); **significantly different from L-NAME-OVX (P < 0.05).
Contractile function of the different experimental groups before ischemia and after reperfusion.
| Before Ischemia | After Reperfusion | |||||
|---|---|---|---|---|---|---|
| HR (bpm) | LVEDP (mmHg) | LVDP (mmHg) | HR (bpm) | LVEDP (mmHg) | LVDP (mmHg) | |
| TYRODE | ||||||
| SHAM | 214 ± 27 | 10 ± 1 | 94 ± 21 | 188 ± 27 | 58 ± 12 | 21 ± 9 |
| OVX | 201 ± 38 | 10 ± 1 | 87 ± 20 | 176 ± 46 | 63 ± 23 | 31 ± 27 |
| OVX + E2 | 184 ± 31 | 10 ± 1 | 95 ± 15 | 169 ± 28 | 62 ± 24 | 33 ± 21 |
| L-NAME | ||||||
| SHAM | 202 ± 39 | 10 ± 1 | 100 ± 15 | 190 ± 50 | 55 ± 21 | 38 ± 30 |
| OVX | 206 ± 36 | 9 ± 1 | 84 ± 30 | 195 ± 31 | 57 ± 23 | 32 ± 19 |
| OVX + E2 | 186 ± 42 | 10 ± 1 | 99 ± 15 | 165 ± 58 | 66 ± 31 | 36 ± 29 |
Values are expressed as mean ± S.D. of 4–6 animals/group. Heart rate (HR), left ventricle end diastolic pressure (LVEDP), left ventricular developed pressure (LVDP).
Figure 2Hydrogen peroxide (H2O2) concentration (in μmol g tissue−1) in cardiac tissue slices (a) and nitrites (NO2 −) and nitrates (NO3 −) concentration (in mmol L−1) in cardiac muscle homogenates (b) of the different experimental groups at the end of reperfusion. Values are expressed as mean ± S.D. of 4–6 animals/group. *Significantly different from TYRODE-SHAM (P < 0.05); †significantly different from TYRODE-OVX + E2 (P < 0.05).
Antioxidant activity in cardiac muscle homogenates of the different experimental groups at the end of reperfusion.
| SOD (U mg prot.−1) | CAT (pmol mg prot.−1) | |
|---|---|---|
| TYRODE | ||
| SHAM | 13.3 ± 2.0 | 22.4 ± 1.7 |
| OVX | 11.7 ± 0.9 | 26.9 ± 0.7* |
| OVX + E2 | 11.9 ± 1.2 | 20.8 ± 2.2** |
| L-NAME | ||
| SHAM | 14.4 ± 1.7 | 26.6 ± 2.0* |
| OVX | 12.0 ± 0.7 | 27.9 ± 2.6 |
| OVX + E2 | 12.2 ± 2.8 | 27.4 ± 3.1† |
Values are expressed as mean ± S.D. of 4–6 animals/group.
*significantly different from TYRODE-SHAM (P < 0.05); **significantly different from TYRODE-OVX (P < 0.05); †significantly different from TYRODE-OVX + E2 (P < 0.05).